SinoMab Bioscience Ltd. (HK:3681)
:3681
Want to see HK:3681 full AI Analyst Report?
3681 Stock Chart & Stats
HK$1.39
-HK$0.01(-1.00%)
At close: 4:00 PM EST
HK$1.39
-HK$0.01(-1.00%)
Day’s Range― - ―
52-Week RangeHK$1.16 - HK$3.76
Previous CloseN/A
Volume24.00K
Average Volume (3M)6.26M
Market Cap
HK$1.82B
Enterprise ValueHK$1.32B
Total Cash (Recent Filing)HK$382.40M
Total Debt (Recent Filing)HK$338.64M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding1,386,638,300
10 Day Avg. Volume8,278,616
30 Day Avg. Volume6,255,789
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)2.91
Price to Sales (P/S)0.00
P/FCF Ratio-15.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)HK$8.71M
Bulls Say, Bears Say
Bulls Say
Focused Antibody R&D And Commercialization StrategyA dedicated monoclonal-antibody R&D and commercialization model provides durable product-lead growth optionality. The firm's strategy to develop antibodies and pursue independent or partnered commercialization reduces standalone commercialization capital needs and preserves strategic flexibility over a multi‑year development cycle.
Material Leverage Improvement In 2025A materially improved leverage profile meaningfully lowers refinancing and solvency risk over the medium term. Reduced debt and stronger equity enhance financial flexibility to fund clinical programs, extend runway, and improve appeal to partners or investors during typical multi‑year biotech development timelines.
Narrower Losses And Improved Free Cash Flow Burn PaceProgress toward narrower net losses and a slower free‑cash‑flow burn suggests operational discipline and better cash stewardship. Improving cash consumption extends runway, reduces near‑term funding urgency, and supports continued clinical development without immediate dilutive financing if trends persist over subsequent quarters.
Bears Say
Zero Reported Revenue In 2025A full-year revenue collapse to zero indicates the company lacks commercialized products and remains purely development‑stage. This structurally shifts valuation and sustainability onto successful clinical outcomes or partner deals; absent near‑term approvals, the business faces long timelines before operating revenue can underpin costs.
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow demonstrates structural cash burn to fund R&D. Reliance on external financing to sustain operations increases dilution and refinancing risk, constraining long‑term planning and making progress dependent on capital markets or partner transactions amid uncertain clinical outcomes.
Consistent Net Losses And Deeply Negative Returns On CapitalOngoing, material net losses and negative returns on equity indicate the company is destroying shareholder capital absent successful product commercialization. This raises persistent funding needs and heightens execution risk: if clinical or partner milestones slip, future financing may be more costly or dilutive, eroding long‑term equity value.
SinoMab Bioscience Ltd. News
3681 FAQ
What was SinoMab Bioscience Ltd.’s price range in the past 12 months?
SinoMab Bioscience Ltd. lowest stock price was HK$1.16 and its highest was HK$3.76 in the past 12 months.
What is SinoMab Bioscience Ltd.’s market cap?
SinoMab Bioscience Ltd.’s market cap is HK$1.82B.
When is SinoMab Bioscience Ltd.’s upcoming earnings report date?
SinoMab Bioscience Ltd.’s upcoming earnings report date is Aug 24, 2026 which is in 95 days.
How were SinoMab Bioscience Ltd.’s earnings last quarter?
SinoMab Bioscience Ltd. released its earnings results on Mar 23, 2026. The company reported -HK$0.044 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.044.
Is SinoMab Bioscience Ltd. overvalued?
According to Wall Street analysts SinoMab Bioscience Ltd.’s price is currently Overvalued.
Does SinoMab Bioscience Ltd. pay dividends?
SinoMab Bioscience Ltd. does not currently pay dividends.
What is SinoMab Bioscience Ltd.’s EPS estimate?
SinoMab Bioscience Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SinoMab Bioscience Ltd. have?
SinoMab Bioscience Ltd. has 1,386,638,300 shares outstanding.
What happened to SinoMab Bioscience Ltd.’s price movement after its last earnings report?
SinoMab Bioscience Ltd. reported an EPS of -HK$0.044 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.183%.
Which hedge fund is a major shareholder of SinoMab Bioscience Ltd.?
Currently, no hedge funds are holding shares in HK:3681
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SinoMab Bioscience Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.64%
12-Months-Change
Fundamentals
Return on Equity
-27.70%
Trailing 12-Months
Asset Growth
26.20%
Trailing 12-Months
Company Description
SinoMab Bioscience Ltd.
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, as well as in phase 1 clinical trial to treat multiple sclerosis, SLE, and NMOSD. Its products under the preclinical stage comprise SM17 for the treatment of asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06 to treat RA, SLE, NMOSD, and SS; SM09 for the treatment of NHL and RA; and TNF2 for the treatment of autoimmune diseases. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Technical Analysis
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Lepu Biopharma Co. Ltd. Class H
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―